Efficacy and tolerability of intravenous levetiracetam in childrens.

Front Neurol

Department of Pediatrics, Division of Pediatric Neurology, Texas A&M Health Science Center College of Medicine, Scott & White Hospital, Temple, TX , USA.

Published: August 2013

Intractable epilepsy in children poses a serious medical challenge. Acute repetitive seizures and status epilepticus leads to frequent emergency room visits and hospital admissions. Delay of treatment may lead to resistance to the first-line anticonvulsant therapies. It has been shown that these children continue to remain intractable even after acute seizure management with approved Food and Drug Administration (FDA) agents. Intravenous levetiracetam, a second-generation anticonvulsant was approved by the FDA in 2006 in patients 16 years and older as an alternative when oral treatment is not an option. Data have been published showing that intravenous levetiracetam is safe and efficacious, and can be used in an acute inpatient setting. This current review will discuss the recent data about the safety and tolerability of intravenous levetiracetam in children and neonates, and emphasize the need for a larger prospective multicenter trial to prove the efficacy of this agent in acute seizure management.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743038PMC
http://dx.doi.org/10.3389/fneur.2013.00120DOI Listing

Publication Analysis

Top Keywords

intravenous levetiracetam
16
tolerability intravenous
8
acute seizure
8
seizure management
8
efficacy tolerability
4
intravenous
4
levetiracetam
4
levetiracetam childrens
4
childrens intractable
4
intractable epilepsy
4

Similar Publications

Childhood-onset focal epilepsy and acute para-infectious encephalopathy in a patient with biallelic QARS1 variants.

Neurol Sci

December 2024

Neurophysiopathology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Introduction: Biallelic variants in QARS1, a house-keeping gene involved in protein synthesis, cause a rare encephalopathy classically characterized by severe developmental delay, drug-resistant neonatal-onset epilepsy, microcephaly, and brain atrophy. We aim to raise awareness on mild QARS1-related phenotypes describing a 6-year-old patient.

Case Description: Epilepsy onset occurred at 3.

View Article and Find Full Text PDF

Strategies to innovate emergency care of status epilepticus.

Neurotherapeutics

December 2024

Department of Neurology and Neuroscience Brain Institute University of Virginia, School of Medicine, Health Sciences Center, Box 801330, Charlottesville, VA 22908-1330, USA. Electronic address:

Generalized Convulsive status epilepticus (SE) is a neurological emergency because prolonged convulsions can cause respiratory compromise and neuronal injury. Compromised GABA-mediated inhibition is a defining feature of SE, and many current therapies are benzodiazepines, which are allosteric modulators of GABA-A receptors. Many patients with medically refractory epilepsy are at risk for SE.

View Article and Find Full Text PDF

Japanese guidelines for treatment of pediatric status epilepticus - 2023.

Brain Dev

December 2024

Working Group for the Revision of Treatment Guidelines for Pediatric Status Epilepticus/Convulsive Status Epilepticus, Japanese Society of Child Neurology, Tokyo, Japan; Committee for Integration of Guidelines, Japanese Society of Child Neurology, Tokyo, Japan; Division of Child Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan.

Article Synopsis
  • The 2015 updated definition of status epilepticus (SE) emphasizes the importance of early treatment, identifying key time points for diagnosis and management.
  • Japan has revised its pediatric SE treatment guidelines, recommending buccal midazolam for pre-hospital and in-hospital treatment when intravenous access is not possible, while benzodiazepines are preferred when intravenous access is available.
  • The updated guidelines note similarities in seizure cessation rates across different medications, highlight the need for further recommendations on nonconvulsive status epilepticus (NCSE), and plan to explore the effects of NCSE treatment on children's outcomes in future editions.
View Article and Find Full Text PDF

Background: Progressive multifocal leukoencephalopathy (PML) is a severe opportunistic brain disease caused by lytic JC polyomavirus (JCPyV) replication in oligodendrocytes. Although JCPyV infection is common in the general population, PML almost exclusively occurs in patients immunocompromised due to untreated HIV/AIDS, haematological malignancies, primary immunodeficiencies, solid organ transplantation, or immunomodulatory treatment of autoimmune diseases. There is no effective antiviral treatment, and recovery depends on immune reconstitution.

View Article and Find Full Text PDF

Background: Stevens-Johnson Syndrome (SJS) is an infrequent yet severe mucocutaneous reaction that involves less than 10% of the Body Surface Area (BSA). It is predominantly induced by certain medications, including anticonvulsants (e.g.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!